Story perspectives

Hutchmed Sells 45% Stake for $608M to Boost Cancer Focus

1/2/2025

27 4

Summary

Story summary

Hutchmed, led by Li Ka-shing, is selling a 45% stake in Shanghai Hutchison Pharmaceuticals for approximately $608 million to enhance capital and concentrate on cancer treatments.
The sale comprises a 35% stake to GP Health Service Capital and 10% to Shanghai Pharmaceuticals.
Hutchmed anticipates a pre-tax gain of $477 million, intending to reinvest in its core operations.
The transaction is expected to finalize by the end of Q1, subject to regulatory approvals.

1 of 1

Story summary

Hutchmed, led by Li Ka-shing, is selling a 45% stake in Shanghai Hutchison Pharmaceuticals for approximately $608 million to enhance capital and concentrate on cancer treatments.
The sale comprises a 35% stake to GP Health Service Capital and 10% to Shanghai Pharmaceuticals.
Hutchmed anticipates a pre-tax gain of $477 million, intending to reinvest in its core operations.
The transaction is expected to finalize by the end of Q1, subject to regulatory approvals.